Diagnostear Technologies, Inc. · CSE:DTR
Diagnostear Technologies — Investor Presentation (January 2025)
17 slides from Diagnostear Technologies's investor presentation, January 2025
Slide 1: Developing innovative diagnostic tools for assessing eye diseases
Developing innovative diagnostic tools for assessing eye diseases Corporate Presentation | January 2025 | CSE: DTR
Slide 2: Forward looking information
Forward looking information This presentation was prepared by DiagnosTear Technologies Inc. (“DiagnosTear") and contains summary information only. It does not include a detailed and/or complete description of DiagnosTear, its subsidiaries, and holdings (collectively, the "Company"), its activities o
Slide 3: Our Vision
OUR VISION YOUR TEARS CONTAIN CRITICAL INFORMATION DiagnosTear aims to become the global leader in rapid, tear-based ophthalmic diagnostics Corporate Presentation | CSE: DTR 3
Slide 4: Market Opportunity
Market Opportunity Dry Eye Red Eye • Allergic conjunctivitis: 6M+ Annually – 344M patients in the U.S.2,3 patients globally; • Adenoviral conjunctivitis: 20M patients in the U.S.4 over 20M • Herpetic keratitis: 1.5M patients in the patients globally and 500K in U.S.1 the U.S.5 1. Gabrielle Weiner, C
Slide 5: Dry Eye – The Problem
Dry Eye – The Problem Dry Eye Syndrome - 350M patients globally Diagnosis is complex – requires many tests General Ophthalmologists lack skill and experience to diagnose Dry Eye Current tests lack consistency and often do not associate with each other Aqueous deficient, or evaporative dry eye – curr
Slide 6: TeaRx Dry Eye
The Solution: How to use TeaRxTM Dry Eye Test? TeaRxTM Dry Eye Received Regulatory Approval: 1 Microfluidic collection of tear liquid 2 Multifactorial assessment of biomarkers in the tear film 3 Intuitive interpretation of results via smart algorithms Results from a clinical trial (600 subjects): On
Slide 7: Red Eye – The Problem
Red Eye – The Problem Cause Prevalence Treatment Remarks Adenovirus Adenoviral conjunctivitis ~80% Of all acute Proper hygiene Steroids Steroids to relieve symptoms (only by ophthalmologist) conjunctivitis cases Rare, Dangerous. Herpes Herpetic ~1-3% Acyclovir Major contraindication for steroids Ker
Slide 8: TeaRx Red Eye
The Solution: How to use TeaRxTM Red Eye? TeaRxTM Red Eye Innovative point of care test for differential diagnosis (Herpetic Keratitis, Adenoviral conjunctivitis & Allergic conjunctivitis) For primary care setups (GP, ER, etc.) as well as ophthalmologists Operation can be performed by a nurse US Pat
Slide 9: Competitive Landscape
Competitive Landscape Indication Company Product Drawbacks Inflammadry® • Aggressive brushing of the conjunctiva (MMP9) test • Only for detection of inflammatory dry eye (NASDAQ: QDEL) ScoutPro tear • Only for detection of evaporative dry eye DRY EYE (NYSE: BLCO) Osmolarity test • 64% Sensitivity1 •
Slide 10: TeaRx Roadmap
TeaRxTM Roadmap R&D Validations Clinical Trials Regulatory Commercialization (CE/FDA) TeaRxTM IN PROGRESS Dry Eye (CE-Approved) TeaRxTM IN PROGRESS IN PROGRESS TO BE COMPLETED TO BE COMPLETED Red Eye (2025) (2025) (CE + FDA) (2026) Corporate Presentation | CSE: DTR 10
Slide 11: Growth Strategy (2025 – 2026)
Growth Strategy (2025 – 2026) Growth Strategy (2025 – 2026): Dry Eye Red Eye • Expansion into key global markets • Finalization of the clinical validation of the TeaRxTM Red Eye • Strategic collaborations with prototype pharma companies for using TeaRxTM Dry Eye as a companion • Regulatory readiness
Slide 12: Intellectual Property
Intellectual Property Granted Description/Family Patent No. Territories Expiry Method For Measuring Tear EP3288458 EU (Switzerland, Germany, Spain, France, United May 1st, 2036 Constitutes in A Tear Sample Kingdom, Liechtenstein, Netherlands) IL255311 Israel Sep 14th, 2036 US10,527,628 USA Sep 14th,
Slide 13: Worldwide Connections
Worldwide Connections Country Organization Description CRO specializing in Ophthalmology – offering our Dry eye test to USA pharma companies be used for screening and monitoring in clinical trials Leumit HMO – Red Eye clinical trial Kaplan Hospital – Red Eye clinical trial Shaare Zedek Medical Cente
Slide 14: Our Management Team
Our Management Team Yaacov Michlin Dr. Shimon Gross Chairman of the Board Chief Executive Officer • CEO - BioLight (TASE:BOLT) • >20 years experience in IVD • Co-chairman – IATI • Ex VP Genomics division– AID Genomics • Ex CEO – BrainsWay (Led to NASDAQ • Ex VP Sales & Marketing - Savyon Diagnostics
Slide 15: Share Ownership
Share Ownership 44% 46% Public Float 10% Corporate Presentation | CSE: DTR 15
Slide 16: Key Investment Highlights
Key Investment Highlights TeaRxTM Dry Eye TeaRxTM Red Eye Robust Growth Opportunities • First & only product providing • First product to provide a complete • Scalable production line for the information on severity and root diagnostic solution for all 3 common commercially-ready dry eye product cau
Slide 17: Contact Us
CSE: DTR CONTACT US E-mail: info@Diagnostear.com or ir@Diagnostear.com Website: http://Diagnostear.com Corporate Presentation | CSE: DTR 17
DiagnosTear Technologies — Investor Presentation (January 2025) on 6ix